Sequana Medical has successfully secured an additional €6.3 million in convertible financing from SFPIM and other existing shareholders, bringing the total raised under its 2025 Convertible Loan to €10.3 million. This strategic fundraising effort builds on previous investments from EQT and Partners in Equity and is designed to extend the company’s cash runway into the first quarter of 2026. The funds will support operational readiness and commercial activities as Sequana prepares for a major milestone—the U.S. launch of its flagship device, the alfapump®, in Q3 2025.

The alfapump® is an FDA-approved, implantable medical device developed to treat recurrent or refractory ascites—a debilitating fluid buildup caused by liver cirrhosis that significantly impacts patient quality of life. Unlike traditional paracentesis procedures that offer temporary relief, the alfapump® provides continuous, automatic removal of ascitic fluid from the abdomen into the bladder, where it is naturally excreted. With over 1,000 implants globally, the device has shown considerable clinical promise and now stands at the brink of broader adoption in the U.S. through a dedicated specialty salesforce targeting liver transplant centers.

This additional funding not only validates the confidence of long-standing investors like SFPIM but also reinforces Sequana’s commitment to addressing serious unmet needs in liver disease management. The capital will enable final preparations for production, regulatory compliance, logistics, and sales deployment for the alfapump’s U.S. rollout. With strong clinical feedback and a growing demand from physicians, Sequana is well-positioned to transform the treatment landscape for ascites and deliver meaningful improvements in patient outcomes.